why choose us

First received: July 29, 2024

Clinical Trial: A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Carcinoma, Non-Small-Cell Lung

Study Type: INTERVENTIONAL


Official Title: 61186372PANSC2003: 61186372PANSC2003 ISA#3 Platform Trial

Brief Summary: The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (expansion).

Read more